WEED:TSX-Canopy Growth Corp (CAD)

COMMON STOCK | Drug Manufacturers-Specialty & Generic | TSX

Last Closing Price

CAD 3.93

Change

+0.16 (+4.24)%

Market Cap

CAD 1.84B

Volume

1.55M

Avg Analyst Target

CAD 6.83 (+73.89%)

Avg User Target

CAD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict


WEED Stock Forecast & Price:
Based on the Canopy Growth Corp stock forecasts from 14 analysts, the average analyst target price for Canopy Growth Corp is CAD 6.83 over the next 12 months. Canopy Growth Corp’s average analyst rating is Hold . Stock Target Advisor’s own stock analysis of Canopy Growth Corp is Bearish, which is based on 2 positive signals and 6 negative signals. At the last closing, Canopy Growth Corp’s stock price was CAD 3.93. Canopy Growth Corp’s stock price has changed by -5.07% over the past week, -21.56% over the past month and -78.86% over the last year.

About Canopy Growth Corp (WEED:CA:TSX)

Canopy Growth Corporation, together with its subsidiaries, engages in the production, distribution, and sale of cannabis and hemp-based products for recreational and medical purposes primarily in Canada, the United States, and Germany. It operates through two segments, Global Can ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-09-27 )

Largest Industry Peers for Drug Manufacturers-Specialty & Generic

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
APHA:CA Aphria Inc

N/A

CAD4.44B 57.08 598.01
BHC:CA Bausch Health Companies Inc

-0.24 (-2.39%)

CAD3.64B 52.89 11.57
TLRY:CA Tilray Inc

+0.14 (+3.76%)

CAD2.22B 6.87 -11.25
CRON:CA Cronos Group Inc

+0.09 (+2.32%)

CAD1.47B 46.76 -0.62
GUD:CA Knight Therapeutics Inc

+0.20 (+3.73%)

CAD0.63B 41.51 28.03
ACB:CA Aurora Cannabis Inc

+0.08 (+5.03%)

CAD0.50B 1,171.00 -0.20
OGI:CA OrganiGram Holdings Inc

+0.04 (+3.33%)

CAD0.38B -99,999.99 -768.87
DHT-UN:CA DRI Healthcare Trust

-0.11 (-1.44%)

CAD0.29B 11.42 N/A
HLS:CA HLS Therapeutics Inc

+0.07 (+0.80%)

CAD0.29B N/A 17.77
TH:CA Theratechnologies Inc.

-0.02 (-0.63%)

CAD0.28B 954.70 -10.18

ETFs Containing WEED:CA

Symbol Name Weight Mer Price(Change) Market Cap
PZC:CA PowerShares FTSE RAFI Can.. 0.00 % 0.68 %

N/A

CAD7.18M
HMMJ:CA Horizons Medical Marijuan.. 0.00 % 0.85 %

+0.04 (+0.65%)

CAD0.18B
SEED:CA Evolve Marijuana Fund 0.00 % 0.75 %

N/A

CAD3.63M
HMMJ-U:CA Horizons Marijuana Life S.. 0.00 % 0.85 %

N/A

CAD0.15B

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers-Specialty & Generic)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -64.40% 29% F 3% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -64.40% 29% F 3% F
Trailing 12 Months  
Capital Gain -78.23% 26% F 2% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -78.23% 26% F 2% F
Trailing 5 Years  
Capital Gain -63.31% 30% F 10% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -63.31% 30% F 9% F
Average Annual (5 Year Horizon)  
Capital Gain 3.17% 81% B- 49% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 3.17% 81% B- 42% F
Risk Return Profile  
Volatility (Standard Deviation) 91.95% 10% F 8% F
Risk Adjusted Return 3.45% 81% B- 28% F
Market Capitalization 1.84B 94% A 78% C+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers-Specialty & Generic)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 1.12 32% F 55% F
Price / Cash Flow Ratio -3.37 65% D 79% C+
EV/EBITDA -0.86 66% D 74% C
Management Effectiveness  
Return on Equity -93.84% 39% F 6% F
Return on Invested Capital -13.49% 59% F 14% F
Return on Assets -7.69% 48% F 14% F
Debt to Equity Ratio 41.55% 35% F 56% F
Technical Ratios  
Dividend Yield N/A N/A N/A N/A N/A
Short Ratio 4.37 39% F 41% F
Short Percent 3.87% 11% F 21% F
Beta 2.07 25% F 10% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (CAD)

Quarterly Financials (CAD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

Discussions

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector